Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69189-5241-01 69189-5241 Anagrelide Hydrochloride Anagrelide Hydrochloride 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral July 15, 2015 May 24, 2017 No Longer Used
69656-0101-02 69656-0101 Rolapitant Varubi 90.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 7, 2015 Oct. 31, 2021 No Longer Used
70934-0384-06 70934-0384 Metoclopramide Metoclopramide 10.0 mg/1 Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Oral June 3, 2019 In Use
70934-0548-30 70934-0548 Metoclopramide Metoclopramide 10.0 mg/1 Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Oral Feb. 26, 2020 In Use
76045-0101-20 76045-0101 Metoclopramide Hydrochloride Metoclopramide 10.0 mg/2mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous May 3, 2013 In Use
13668-0453-01 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0453-30 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0453-74 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-01 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-30 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-74 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
23155-0547-31 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 22, 2016 In Use
23155-0547-41 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 15, 2012 In Use
23155-0547-42 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 15, 2012 In Use
23155-0548-31 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 22, 2016 In Use
23155-0548-41 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 9, 2015 In Use
23155-0548-42 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 9, 2015 In Use
11994-0016-01 11994-0016 samarium Sm 153 lexidronam Quadramet 50.0 mCi/mL Ancillary Therapy Radiopharmaceutical Samarium Sm 153 Intravenous May 19, 1997 In Use
23155-0356-32 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
23155-0356-41 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
69452-0350-01 69452-0350 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2022 In Use
69452-0350-11 69452-0350 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2022 In Use
69452-0350-92 69452-0350 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 28, 2022 In Use
70121-1569-07 70121-1569 Filgrastim RELEUKO 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1571-07 70121-1571 Filgrastim RELEUKO 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
49884-0867-01 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0867-02 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 30, 2008 Jan. 31, 2020 In Use
49884-0867-05 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0867-15 49884-0867 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-01 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-02 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 30, 2008 Feb. 29, 2020 In Use
49884-0868-05 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0868-15 49884-0868 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-01 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-02 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 30, 2008 Feb. 29, 2020 In Use
49884-0869-05 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
49884-0869-15 49884-0869 Dronabinol Dronabinol 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 27, 2008 In Use
45865-0598-10 45865-0598 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 3, 2015 In Use
45865-0598-30 45865-0598 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 3, 2015 In Use
00078-0675-15 00078-0675 ondansetron hydrochloride ZOFRAN 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 7, 2018 May 31, 2022 No Longer Used
00078-0676-15 00078-0676 ondansetron hydrochloride ZOFRAN 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 12, 2017 May 31, 2022 No Longer Used
17478-0547-01 17478-0547 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2009 In Use
51991-0065-97 51991-0065 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 1, 2020 May 2, 2020 No Longer Used
51991-0065-98 51991-0065 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Sept. 15, 2017 May 31, 2022 No Longer Used
68001-0366-25 68001-0366 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Oct. 5, 2018 May 31, 2022 No Longer Used
68001-0366-87 68001-0366 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Feb. 10, 2020 Aug. 24, 2021 No Longer Used
53097-0571-60 53097-0571 Dronabinol MARINOL 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use
67457-0440-00 67457-0440 Ondansetron Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 10, 2017 In Use
67457-0440-22 67457-0440 Ondansetron Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 29, 2014 In Use
67877-0753-60 67877-0753 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 In Use

Found 10,000 results in 6 milliseconds — Export these results